Technical Analysis for PPBT - Purple Biotech Ltd.

Grade Last Price % Change Price Change
F 3.11 -3.12% -0.10
PPBT closed down 3.12 percent on Friday, November 1, 2024, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 19
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -3.12%
NR7 Range Contraction -3.12%
NR7-2 Range Contraction -3.12%
Narrow Range Bar Range Contraction -3.12%

   Recent Intraday Alerts

Alert Time
Down 5% about 21 hours ago
Fell Below Lower Bollinger Band about 21 hours ago
New 52 Week Low about 21 hours ago
Possible NR7 about 22 hours ago
60 Minute Opening Range Breakdown 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Purple Biotech Ltd. Description

Purple Biotech Ltd. (f/k/a Kitov Pharma Ltd.) (the “Company”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a phase 1/2 study. CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. The Company plans to advance CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company is relocating its corporate headquarters imminently to Rehovot, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Cancer Treatment Tumor FDA Hypertension Non Small Cell Lung Cancer Antineoplastic Drugs Pancreatic Cancer Lung Cancer Breakthrough Therapy Osteoarthritis Advanced Solid Tumors Checkpoint Inhibitor Non Small Cell Lung Carcinoma Novel Cancer Treatment Of Non Small Cell Lung Cancer Treatment Of Osteoarthritis Health Effects Of Tobacco Pd 1 Programmed Cell Death Protein 1

Is PPBT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.8
52 Week Low 3.0
Average Volume 36,238
200-Day Moving Average 10.11
50-Day Moving Average 6.03
20-Day Moving Average 4.04
10-Day Moving Average 3.86
Average True Range 0.57
RSI (14) 27.54
ADX 58.08
+DI 8.00
-DI 32.00
Chandelier Exit (Long, 3 ATRs) 4.22
Chandelier Exit (Short, 3 ATRs) 4.70
Upper Bollinger Bands 5.08
Lower Bollinger Band 3.00
Percent B (%b) 0.05
BandWidth 51.28
MACD Line -0.70
MACD Signal Line -0.69
MACD Histogram -0.0169
Fundamentals Value
Market Cap 79.97 Million
Num Shares 25.7 Million
EPS -1.05
Price-to-Earnings (P/E) Ratio -2.96
Price-to-Sales 58.08
Price-to-Book 0.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.74
Resistance 3 (R3) 3.77 3.60 3.64
Resistance 2 (R2) 3.60 3.44 3.58 3.60
Resistance 1 (R1) 3.35 3.34 3.27 3.32 3.56
Pivot Point 3.18 3.18 3.13 3.16 3.18
Support 1 (S1) 2.93 3.02 2.85 2.90 2.66
Support 2 (S2) 2.76 2.92 2.74 2.62
Support 3 (S3) 2.51 2.76 2.59
Support 4 (S4) 2.48